A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

Study Identifier
M26-216
CT.gov Identifier
NCT07673120
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Recruiting
Sign up for trial alerts

Study Details

Medical Condition
  • Healthy Volunteer
    • Study Drug
  • ABBV-313
  • Placebo
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 55 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * BMI is \>= 18.0 to \<= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
    Exclusion Criteria:
    * History of any clinically significant sensitivity or allergy to any medication or food. * History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment. * Participant has prior exposure to ABBV-313 within the past 300 days.

    Protocol Summary

    The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.

    Study Locations

    Location
    Status
    Location
    Acpru /Id# 283495
    Grayslake, Illinois, United States, 60030
    Status
    Recruiting